{"classes":[{"categories":[{"measurements":[{"comment":"Too few deaths occurred to estimate an upper 95% CI.","groupId":"OG000","lowerLimit":"6.5","upperLimit":"NA","value":"11.5"},{"groupId":"OG001","lowerLimit":"11.1","upperLimit":"21.9","value":"16.3"},{"groupId":"OG002","lowerLimit":"9.7","upperLimit":"18.1","value":"14.8"},{"groupId":"OG003","lowerLimit":"25.2","upperLimit":"38.3","value":"32.7"},{"comment":"Too few deaths occurred to estimate an upper 95% CI.","groupId":"OG004","lowerLimit":"14.6","upperLimit":"NA","value":"35.0"},{"comment":"Too few deaths occurred to estimate a median or an upper 95% CI.","groupId":"OG005","lowerLimit":"30.6","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"58"},{"groupId":"OG005","value":"24"}],"units":"Participants"}],"description":"Survival time will be defined as the time from registration to death. Time to event distributions will be estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Endometrial Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Ovarian Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Hepatocellular Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Carcinoid Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Islet Cell (Double Agent) Cohort"},{"description":"Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Islet Cell (Bevacizumab-only) Cohort"}],"paramType":"MEDIAN","populationDescription":"All patients that received study intervention and were followed for survival were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Time from registration to death, assessed up to 3 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}